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INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting about 1 to 2% of individuals aged 65 years
or older, with a prevalence projected to increase substantially as the
global population ages (1). Over the many years that patients with
PD live with the disease, disabling motor and nonmotor symptoms
emerge (2). Whereas current therapies can temporarily improve
motor symptoms and provide some benefit for nonmotor symptoms,
a major unmet need remains to identify disease-modifying treatments
to reduce the progression of PD.
Variants in leucine-rich repeat kinase 2 (LRRK2) are one of the most
common genetic risk factors in PD. LRRK2G2019S, the most common
pathogenic variant in LRRK2, accounts for a high proportion (about
4 to 5%) of familial PD cases and about 1% of sporadic PD cases (3).
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In addition, genome-wide association studies have shown that
common noncoding variants at the LRRK2 locus confer risk for PD
(4). Several PD-associated LRRK2 variants increase LRRK2 kinase
activity, resulting in excessive phosphorylation of substrates. These
substrates include a subset of Rab guanosine triphosphates (GTPases)
that act as master regulators of intracellular trafficking (5). As LRRK2
variants increase the phosphorylation of several Rab GTPases and
can affect their ability to interact with downstream effectors, LRRK2
kinase activity has been shown to play a role in regulating many
aspects of membrane trafficking, including autophagy, retrograde
transport from endosomes to the trans-Golgi network, and lysosomal function (6). In particular, LRRK2 activity can affect various
aspects of endolysosomal function, including autophagic flux, protein degradation, and response to lysosomal damage (7).
Inhibition of LRRK2 activity and the consequent improvement
of membrane trafficking and lysosomal function is a promising new
approach for disease modification in PD (7). In addition to patients
with PD who have LRRK2 variants, increased LRRK2 activity has
also been observed in patients with other genetic forms of PD (e.g.,
the D620N mutation in VPS35) and with nonhereditary idiopathic
PD (8–10). Furthermore, increasing evidence from human genetic
studies and preclinical PD animal models emphasizes that lysosomal
dysfunction is a common hallmark of PD and suggests that therapeutic approaches aimed at improving PD-linked defects in lysosomal homeostasis, including LRRK2 inhibition, may meaningfully
affect disease progression (11). For example, variants in the
GBA gene, which encodes the lysosomal enzyme glucocerebrosidase
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Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors for Parkinson’s
disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal function and may contribute to the
pathogenesis of PD. Thus, inhibition of LRRK2 is a potential disease-modifying therapeutic strategy for PD. DNL201
is an investigational, first-in-class, CNS-penetrant, selective, ATP-competitive, small-molecule LRRK2 kinase inhibitor.
In preclinical models, DNL201 inhibited LRRK2 kinase activity as evidenced by reduced phosphorylation of both
LRRK2 at serine-935 (pS935) and Rab10 at threonine-73 (pT73), a direct substrate of LRRK2. Inhibition of LRRK2 by
DNL201 demonstrated improved lysosomal function in cellular models of disease, including primary mouse astrocytes and fibroblasts from patients with Gaucher disease. Chronic administration of DNL201 to cynomolgus
macaques at pharmacologically relevant doses was not associated with adverse findings. In phase 1 and phase 1b
clinical trials in 122 healthy volunteers and in 28 patients with PD, respectively, DNL201 at single and multiple
doses inhibited LRRK2 and was well tolerated at doses demonstrating LRRK2 pathway engagement and alteration
of downstream lysosomal biomarkers. Robust cerebrospinal fluid penetration of DNL201 was observed in both
healthy volunteers and patients with PD. These data support the hypothesis that LRRK2 inhibition has the potential
to correct lysosomal dysfunction in patients with PD at doses that are generally safe and well tolerated, warranting
further clinical development of LRRK2 inhibitors as a therapeutic modality for PD.
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in regulating the activity of lysosomal hydrolases and serves as a
biomarker of LRRK2-mediated effects on the lysosome. BMP is
largely localized within the membranes of intralumenal vesicles of
late endosomes and lysosomes. Changes in BMP concentration
reflect functional changes in the lysosomal pathway and have been
used to monitor lysosomal function in patients with lysosomal storage
disorders, e.g., elevated BMP in the urine of patients with Niemann-Pick
disease type C (17, 18). Human LRRK2G2019S carriers have higher
concentrations of urine BMP compared with noncarriers (19).
When LRRK2 activity is absent or reduced, as in LRRK2 knockout
mice or nonhuman primates treated with LRRK2 inhibitors, urine
BMP concentrations are decreased (20). Thus, urinary BMP may be
a useful marker to assess modulation of lysosomal function during
treatment with LRRK2 inhibitors.
DNL201, referred to as GNE-0877 in previous publications
(21, 22), was developed for the treatment of PD. DNL201 is a
first-in-class, selective, ATP (adenosine triphosphate)–competitive,
orally bioavailable, central nervous system (CNS)–penetrant, small-
molecule LRRK2 inhibitor. Compound 1 (Fig. 1A) was first reported
in 2012 as a screening hit from a biochemical LRRK2 high-throughput
screening assay (23). Through structure-based drug design using a
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Fig. 1. Structure and potency of the LRRK2 inhibitor DNL201. (A) Structural comparison of biochemical high-throughput screen hit (compound 1) and DNL201.
DNL201 is referred to as GNE-0877 in previous publications (21). (B and C) Dose-response curves of LRRK2 inhibition by DNL201 as measured by reduction of (B) pS935
and (C) pS1292 in HEK293 cells overexpressing LRRK2G2019S. Dots and error bars indicate mean and SD of data points from two technical replicates in one experiment. IC50
values are geometric means, and ranges represent 95% confidence intervals (CIs): (B) pS935 IC50, 47 nM (43 to 52 nM); (C) pS1292 IC50, 45 nM (39 to 51 nM). (D) Ex vivo treatment
of healthy human PBMCs with DNL201 decreased both pS935 LRRK2 and pT73 Rab10 in a dose-dependent manner (n = 2 donors) in one experiment. Dots and error bars
indicate mean and SD of the two donors. IC50 values are geometric means, and ranges represent 95% CIs. pS935 IC50, 53 nM (43 to 66 nM); pT73 Rab10 IC50, 35 nM (22 to
56 nM). (E) Ex vivo treatment of human iMG with DNL201 treatment decreased both pS935 LRRK2 and pT73 Rab10 in a dose-dependent manner. Data are shown as
means ± SEM; n = 3 independent experiments. IC50 values are geometric means, and ranges represent 95% CIs: pS935 IC50, 30 nM (17 to 53 nM); pT73 Rab10 IC50, 16 nM
(0.4 to 86 nM).
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(GCase), are associated with the lysosomal storage disorder Gaucher
disease and with increased risk for developing PD. Emerging data suggest
that LRRK2 inhibition may lead to increased GCase activity and correct
lysosomal deficits in cellular models carrying GBA variants, suggesting that LRRK2 inhibition may ameliorate lysosomal dysfunction
more broadly than that caused by variants in LRRK2 itself (12, 13).
Markers of LRRK2 activity, such as posttranslational modifications of the protein itself and phosphorylation of downstream Rab
substrates, can serve as tools to indicate the potency of LRRK2 inhibitors. The search for LRRK2 biomarkers in patients with PD has
been extensive but relatively unsuccessful to date. An LRRK2 autophosphorylation site on serine-1292 can be quantified in exogenous
expression systems, and there is evidence that amounts of both pS1292
LRRK2 and pT73 Rab10 in exosomes isolated from urine reflect LRRK2
activity (14, 15). However, these techniques are not easily translatable to quantification of LRRK2 inhibition in human clinical samples
such as urine, cerebrospinal fluid (CSF), blood, or blood-derived cells,
e.g., peripheral blood mononuclear cells (PBMCs) (16).
Lysobisphosphatidic acid, also called BMP [bis(monoacylglycerol)
phosphate], is an atypical, bioactive phospholipid that promotes
lipid sorting in late endosomes and lysosomes. BMP plays a key role
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RESULTS

DNL201 reduces LRRK2 activity and restores lysosomal
function in cellular and animal models
The cellular potency of DNL201, whose structure is shown in Fig. 1A
(21), was assessed in human embryonic kidney (HEK) 293 cells
overexpressing LRRK2G2019S using S935 and S1292 LRRK2 phosphorylation as measures of kinase activity (Fig. 1, B and C). The
potencies for DNL201 using these two LRRK2 phosphorylation
sites were equivalent, with a half-maximal inhibitory concentration
(IC50) in HEK293 cells of 47nM for pS935 LRRK2 and 45nM for
pS1292. Using pS935 LRRK2 and pT73 Rab10 as readouts of LRRK2
inhibition, comparable potencies were measured in human PBMCs
expressing wild-type LRRK2 (IC50 of 53 and 35 nM, respectively)
(Fig. 1D). DNL201 treatment also led to a dose-dependent decrease in
pS935 LRRK2 and pT73 Rab10 (IC50 of 30 and 16 nM, respectively)
in human-induced pluripotent stem cell (iPSC)–derived microglia
(iMG), confirming that similar inhibition was observed in relevant
human CNS cells (Fig. 1E). To measure the potency of DNL201 in human cells expressing LRRK2G2019S, human PBMCs from LRRK2G2019S
carriers and controls were analyzed ex vivo. Treatment with DNL201
effectively inhibited LRRK2 phosphorylation, with about twofold
increase in potency of DNL201 in PBMCs from LRRK2G2019S carriers
versus controls (mean IC50, 22 versus 50 nM) (fig. S1A). Increased potency
of DNL201 was also observed in primary cortical neurons from
LRRK2G2019S knockin mice compared to wild-type controls (fig. S1B).
Next, the ability of DNL201 to rescue lysosomal defects in cellular
models of disease was evaluated. Consistent with previous findings,
overexpression of fluorescently tagged LRRK2G2019S in human H4
neuroglioma cells led to enlarged lysosomes that coalesced and
showed a perinuclear distribution (Fig. 2A) (24). DNL201 treatment
restored lysosome size and morphology to that observed in cells
expressing wild-type LRRK2 (Fig. 2A). To assess the effects of
DNL201 on lysosomal function, the extent of lysosomal protein
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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degradation was measured in wild-type and LRRK2G2019S cells using a
cellular model with endogenous expression of LRRK2G2019S, that is,
primary mouse astrocytes derived from LRRK2G2019S knockin mice.
Primary astrocytes from LRRK2G2019S knockin mice showed a reduction in lysosomal protein degradation compared with cells
derived from wild-type mice. After DNL201 treatment, lysosomal
protein degradation was normalized back to wild-type levels in the
LRRK2G2019S primary mouse astrocytes (Fig. 2B; P < 0.05 and P < 0.01).
LRRK2 inhibition may also correct disease-associated lysosomal
dysfunction independent of LRRK2 mutation status. Patients who
have homozygous loss-of-function mutations in the gene GBA
can develop the lysosomal storage disorder Gaucher disease, and
patients who have heterozygous GBA mutations have an increased risk
for PD (25). Furthermore, recent findings in astrocytes from
GBAD409V knockin mice and iPSC-derived dopaminergic neurons
from GBA variant carriers have shown that LRRK2 inhibition can
boost GCase activity and correct downstream defects, suggesting
that LRRK2 inhibition may be beneficial in normalizing lysosomal
dysfunction caused by GBA variants (12, 13, 26). To assess the ability
of LRRK2 inhibition to correct lysosomal dysfunction more broadly,
fibroblasts from patients with Gaucher disease were treated with
DNL201 (Fig. 2C). Treatment with DNL201 partially corrected
dysfunctional lysosomal protein turnover in this aggressive cellular
model of GBA-linked lysosomal dysfunction, suggesting that DNL201
treatment may correct lysosomal dysfunction not directly caused by
variants in LRRK2 (Fig. 2C; P < 0.01).
DNL201 inhibits LRRK2 activity both in the periphery
and CNS in animal models
The potency of DNL201 was assessed in the kidney and brain tissue
of rats 1 hour after oral administration of DNL201 at 3, 10, 30, or
60 mg/kg. DNL201 inhibited pS935 LRRK2 in a dose-dependent
manner in both kidney and brain tissue compared with vehicle-
treated animals 1 hour after a single dose (Fig. 3, A and B, and fig. S2).
By comparing drug exposure and pS935 LRRK2 inhibition in rat
brain, an unbound IC50 of 52 nM in brain was calculated.
In vivo pharmacology was also assessed in cynomolgus macaques.
Briefly, DNL201 (0.5 mg/kg) was administered by intravenous bolus
injection to macaques that had a surgically implanted catheter in
the cisterna magna for sampling of CSF. The unbound DNL201
concentrations were similar in plasma and CSF, indicating that
measurement of DNL201 in blood correlated with the concentration
in brain tissue (Fig. 3C). To assess the pharmacodynamic effects of
DNL201 in the periphery and the CNS, PBMCs and brain tissues
were collected from cynomolgus macaques treated with DNL201
for 28 days and euthanized 24 hours after the last dose. DNL201
exhibited similar dose-dependent inhibition of LRRK2 activity in
PBMCs and brain homogenates from the animals as measured by
pS935 LRRK2 (Fig. 3D), demonstrating that CNS pharmacodynamic
effects of DNL201 can be predicted using LRRK2 inhibition. A dose-
dependent reduction in phosphorylation of Rab12, a direct substrate
of LRRK2, was also observed in macaque kidney and brain tissue
after DNL201 treatment (fig. S3).
LRRK2 activity regulates the amount of the lysosomal
marker BMP in urine and kidney in animal models
As BMP concentrations are elevated in the urine of LRRK2G2019S
carriers, and LRRK2 inhibition can reduce urinary BMP in rodents
and nonhuman primates (19, 20), the effect of LRRK2 inhibition on
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validated LRRK2 homology model and CNS-focused medicinal
chemistry optimization, Estrada et al. discovered aminopyrazole DNL201 [2-methyl-2-(3-methyl-4-((4-(methylamino)-5-
(trifluoromethyl)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)
propanenitrile, GNE-0877] (21). Off-target kinase profiling showed
that DNL201 is a highly specific LRRK2 inhibitor with an acceptable
in vitro biochemical selectivity window against off-target kinases.
In vitro metabolism profiling of DNL201 revealed low turnover in
human microsomes, and permeability assessment demonstrated
that DNL201 is not a P-glycoprotein [MDCK-MDR1 (Madin-Darby
canine kidney cells transfected with the human multidrug resistance
1 gene)] or breast cancer resistance protein (BCRP) transporter substrate (21). In vivo systemic pharmacokinetics assessment in preclinical
species (mouse, rat, and cynomolgus macaque) demonstrated low
clearance, moderate half-lives, and good oral bioavailability (21).
In vivo CNS pharmacokinetic experiments across preclinical species
confirmed that ratios of unbound brain and CSF concentrations of
DNL201 to unbound plasma concentrations of DNL201 are near
unity, confirming good penetration of DNL201 into the CNS. In
animal models, LRRK2 inhibition has been associated with microscopic
lung and renal changes, which were demonstrated to be nonadverse
and reversible (20, 22). Here, we present preclinical and clinical studies
of DNL201, including safety, pharmacokinetics, and pharmacodynamics of DNL201 in healthy volunteers and in patients with PD.
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Fig. 2. DNL201 rescues lysosomal defects in cellular models. (A) H4 cells expressing wild-type LRRK2 or mutant LRRK2G2019S were treated with vehicle or DNL201 (0.3 M),
fixed 72 hours after treatment, and stained using an antibody against LAMP1 to assess lysosome morphology. The percentage of cells with enlarged lysosomes was
quantified. Data are shown as means ± SEM from three to five independent experiments *P < 0.05, unpaired t test. Scale bar, 10 m. (B) Primary astrocytes from wild-type
LRRK2 or mutant LRRK2G2019S mice were treated with 2 M DNL201 or DMSO vehicle control for 72 hours, and lysosomal protein degradation was assessed using an AHA-based
assay. Data were normalized to the median within each experiment and then to the wild-type vehicle-treated group. Data are shown as means ± SEM; n = 5 independent
experiments. *P < 0.05 and **P < 0.01, two-way ANOVA adjusted for multiple comparisons using Dunnett’s method. (C) Lysosomal protein turnover in fibroblasts from
healthy human controls and patients with Gaucher disease (GBA L444P variant carriers) after a 72-hour treatment with 2 M DNL201 or DMSO vehicle control. Data were
normalized to the median within each experiment and then to the healthy control, vehicle-treated group. Data are shown as means ± SEM; n = 3 independent experiments.
**P < 0.01 ****P < 0.0001, two-way ANOVA adjusted for multiple comparisons using Dunnett’s method.

BMP in kidney tissue of mice was evaluated to better understand
how changes in urinary BMP relate to lysosomal function changes
in the kidney. For this assessment, a tool LRRK2 inhibitor (MLi-2)
was administered in the diet to wild-type and LRRK2G2019S knockin
mice for seven consecutive days, and the concentration of BMP in
mouse urine and kidney was assessed to determine whether BMP
changes in the kidney could account for LRRK2 activity–dependent
changes in urine BMP. BMP concentrations were reduced in urine
from both wild-type and LRRK2G2019S knockin mice after MLi-2
treatment, which was consistent with previous reports (Fig. 3E)
(20, 22). In the renal cortex, genotype-dependent differences in BMP
in the LRRK2G2019S knockin mice were observed, showing significantly
lower BMP concentrations compared with wild-type littermate
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)

8 June 2022

controls (Fig. 3F; P < 0.05). After LRRK2 inhibition, kidney BMP
concentrations were significantly increased in both wild-type and
LRRK2G2019S knockin mice (Fig. 3, F and G; P < 0.05, P < 0.001, and
P < 0.0001). Whereas it may appear paradoxical that LRRK2 inhibition increased BMP in kidney while decreasing BMP in urine, this
finding is consistent with data demonstrating that BMP can be an
actively secreted lysosomal lipid (27). Together, these results suggest
that LRRK2 inhibition may decrease the extracellular release of
BMP-containing vesicles from kidney cells.
Safety of chronic DNL201 treatment in animals
Previously reported toxicology studies with LRRK2 inhibitors were
short term and included ≤28 days of repeat dosing (20, 22). In a
4 of 17
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8 mice). Individual animal data are plotted (stratified by sex). Gray, WT mice; orange, LRRK2G2019S KI mice. Data are shown as geometric means with 95% CIs. *P < 0.05,
***P < 0.001, ****P < 0.0001 based on an ANCOVA model derived based on an ANCOVA model with terms for treatment, genotype, treatment by genotype interaction,
with adjustment for sex, and for urine, by predose BMP levels, with statistical significance assessed at nominal levels.
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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an LRRK2 substrate that can be measured in PBMCs, could serve as a
proximal marker of LRRK2 activity was investigated. PBMCs were
isolated from LRRK2G2019S mutation carriers (with and without PD),
patients with sporadic PD, and healthy volunteers (controls) (table S4).
As total LRRK2 in human PBMCs varies widely among individuals
(31), the amount of pRab10 was normalized to total LRRK2 as a metric
of LRRK2 activity. After normalizing to total LRRK2, pT73 Rab10
was elevated by about twofold in patients with sporadic PD and in
LRRK2G2019S mutation carriers compared to healthy volunteers
(fig. S5), suggesting elevated LRRK2 activity in these populations.
Other groups have measured pT73 Rab10 or phosphorylation stoichiometry in neutrophils, a subset of cells in peripheral blood that
express both LRRK2 and Rab10, in patients with sporadic PD and
LRRK2G2019S carriers with and without PD. Results from these studies
vary from no detectable increase in pT73 Rab10 to about twofold increase in pT73 Rab10 in LRRK2G2019S carriers versus noncarriers (32–36).
The results of the present study are consistent with this range of
modestly elevated pT73 Rab10 in LRRK2G2019S carriers versus noncarriers, suggesting that ≤2-fold increase in LRRK2 kinase activity
may be sufficient to confer an elevated lifetime risk of developing PD.
Together with other published data on the degree of elevated Rab10
phosphorylation due to LRRK2G2019S (5, 37) and recent data showing
an about twofold increase in LRRK2G2019S kinase activity compared
with wild-type LRRK2 based on an assay of intrinsic LRRK2 kinase
activity (38), these data also suggest that 50% inhibition of LRRK2
kinase activity, at a minimum, may likely be needed in clinical studies
to achieve therapeutic efficacy for slowing disease progression. Although LRRK2G2019S is by far the most common pathogenic LRRK2
variant in the Americas, Europe, and Northern Africa, most PD-
associated LRRK2 variants have also been reported to increase kinase
activity directly or indirectly (39). The degree of elevation of Rab10
phosphorylation in peripheral immune cells or other tissue samples
derived from carriers of these additional PD-causing LRRK2 variants
beyond the G2019S mutation is not yet well defined. Preliminary data
in cell lines, mouse tissues, and neutrophils from a limited number
of LRRK2R1441G carriers suggest that kinase activity for some point
mutations is elevated by more than the twofold seen in LRRK2G2019S
carriers, supporting 50% or greater LRRK2 inhibition as a minimum
target for therapeutic efficacy in clinical studies (5, 33, 37).

LRRK2 activity is increased in patients with sporadic PD and in
LRRK2G2019S carriers relative to non-PD and noncarrier controls
To help define the level of inhibition needed to normalize LRRK2
kinase activity in patients with PD, the question of whether pT73 Rab10,

DNL201 inhibits LRRK2 activity and modulates lysosomal
biomarkers in healthy human volunteers and in patients with PD
Having established the acceptable nonclinical profile of DNL201 in
rodents and nonhuman primates, human testing of LRRK2 inhibition

Table 1. Toxicity and plasma concentrations of DNL201 in cynomolgus macaques after 39 weeks of treatment.
Duration of dosing
(recovery period)

Dosing

Animals (recovery)

Lung histopathology

3 (2)

8 mg/kg BID (16 mg
kg−1 day−1)
16 mg/kg BID (32 mg
kg−1 day−1)

2 mg/kg BID (8 mg kg
day−1)
9 months (3 months)

Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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Observed mean plasma concentrations
Cmax (M)

AUC0–24 (M/hour)

None

0.971

11.0

3 (2)

Minimal increased
vacuolation, type II
pneumocytes

3.09

36.2

3 (2)

Minimal to slightly
increased vacuolation,
type II pneumocytes

7.33

98.9
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chronic toxicity study in macaques lasting 39 weeks, a duration considered suitable to detect late-occurring toxicities and progression
of identified findings (28), DNL201 was tolerated up to the highest
tested dose of 32 mg/kg per day (16 mg/kg twice daily or BID), with
corresponding peak plasma concentration (Cmax) and area under the
plasma concentration-time curve [AUC(0–24h)] values of 7.33 and
98.9 M/hour, respectively (Table 1). No DNL201-related mortality
occurred in this study. In addition, no treatment-related effects on
vital signs were observed, including pulse oximetry and respiration
rates (tables S1A and S1B).
DNL201 treatment was associated with microscopic lung changes
in cynomolgus macaques consisting of vacuolated type II pneumocytes that were nonadverse and reversible (fig. S4 and table S2). The
observed lung effects have been previously described and attributed to
on-target LRRK2 kinase inhibition across multiple compounds (20, 22).
No increase in vacuolated type II pneumocytes was observed in the
lungs of animals receiving 4 mg/kg BID DNL201, whereas minimal
to slightly increased numbers were observed in the lungs of animals
receiving 8 mg/kg BID or 16 mg/kg BID (orally) for 39 weeks (table S2).
These changes were not associated with cellular injury or inflammation when evaluated by light or electron microscopy and did not increase in severity after 9 months of treatment compared with shorter
studies (20, 22). After a 12-week treatment-free period, type II pneumocyte vacuolation was fully reversible (table S2). The original 12-week
and this 39-week study of DNL201 treatment effects revealed similar microscopic lung findings, with no observed clinical pulmonary
dysfunction in nonhuman primates. Because of the lack of progression of the lung changes, clinical signs of pulmonary dysfunction,
or secondary effects (e.g., lung cellular injury or inflammation) in
nonhuman primates, DNL201 is not expected to affect respiratory
function in humans at doses in the therapeutic range.
In the kidneys, reversible, nonadverse, minimally or slightly increased pigment was observed in renal tubular epithelial cells at
>8 mg/kg BID of DNL201 in macaques after 39 weeks of treatment
(table S2). These findings in the kidney are morphologically consistent
with findings described in LRRK2 knockout mice and rats (29, 30).
Clinical pathology evaluation of urinary function included clinical
chemistry, urinalysis, and urine chemistry (table S3, A and B). No
DNL201-related effects on renal function were observed.
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Placebo

Placebo

40 mg BID

100 mg BID

25 mg BID

80 mg BID

80 mg BID (elderly)

A
Day 1

pS935 LRRK2
% change from baseline,
median/IQR

0

−50

Day 28

0

−50
−75

−100
BL

1

3

8
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Pre

1

3

8
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24

BL 1

48

3

8

24 D8 D15 D22 Pre

1

3

8
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Hours/Days after dose
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B

E
Day 1

Day 10

50

0

−50

−100

Day 28
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pT73 Rab10
% change from baseline,
median/IQR

Day 1
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Days
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Day 1

Day 10
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1

3

8

12
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1

3

8
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3

8
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1

3

8
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Hours after dose
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F
Urine BMP concentration
day 28 % change from baseline,
median/IQR

100

Urine BMP concentration
% change from baseline,
median/IQR

50 mg TID

D
50

pS935 LRRK2
% change from baseline,
median/IQR

30 mg TID

50

0

−50

−100
Placebo

25 mg BID 40 mg BID 80 mg BID 100 mg BID

100
50
0
−50
−100

Placebo

30 mg TID

50 mg TID

Fig. 4. Pharmacodynamics of LRRK2 inhibition. The pharmacodynamics of LRRK2 inhibition in healthy volunteers from the phase 1 study MAD cohorts (A to C) and in
patients with PD in the phase 1b study (D to F) is shown. (A and D) pS935 LRRK2 reduction in whole blood in (A) healthy volunteers at days 1 and 10 after treatment with
different doses of DNL201 and (D) in patients with PD at days 1, 8, 15, 22, and 28 after treatment with different doses of DNL201. (B and E) pT73 Rab10 reduction in PBMCs
from (B) healthy volunteers at days 1 and 10 after treatment with different doses of DNL201 and (E) in patients with PD at days 1 and 28 after treatment with different
doses of DNL201. (A to E) Pre, predose (sample collected just before the first dose on that day); BL, baseline (sample collected before the initiation of dosing). Data are
expressed as median percent change from baseline. Error bars show interquartile ranges. (C and F) The reduction in urine BMP (22:6/22:6) normalized to urine creatinine
from a baseline sample collected before the initiation of dosing in (C) healthy volunteers on the 10th day of treatment with different doses of DNL201 (postdose sample
collected as a pooled sample 0 to 6 hours after the last dose) and (F) patients with PD on the 28th day of treatment with different doses of DNL201 (postdose sample
collected as a pooled sample 1 to 6 hours after the last dose). Box plots show median percent change from baseline with interquartile ranges. (A) and (B) n=9-10 placebo,
n=8 each DNL201 group; (C) BID dosing cohorts: n=8 Placebo, n=8 in 25 mg, n=7 in 40 mg, n=6 in 80 mg, n=4 in 100 mg. (D), (E) and (F) TID dosing cohorts: n=7 in placebo,
n=9 in 30 mg, n=11 in 50 mg, n=6 in placebo, n=8 in 30 mg, n=11 in 50 mg.
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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was initiated. Safety, tolerability, pharmacodynamics, and pharmacokinetics of DNL201 were assessed in two human studies: (i) a phase 1,
double-blind, placebo-controlled, first-in-human single ascending
(SAD) and multiple ascending (MAD) dose study in healthy volunteers (NCT04551534) and (ii) a phase 1b, double-blind, placebo-
controlled study enrolling patients with PD, both LRRK2 mutation
carriers and noncarriers (NCT03710707).
In the phase 1 study, target and pathway engagement were evaluated by measuring pS935 LRRK2 in whole blood and pT73 Rab10
in PBMCs of 122 healthy volunteers (Fig. 4). In healthy volunteers
receiving multiple doses of DNL201 for up to 28 days, a dose-
dependent reduction from baseline was observed in pS935 LRRK2
and pT73 Rab10 (Fig. 4, A and B, and fig. S6). DNL201 exhibited
strong LRRK2 inhibition, measured by whole-blood pS935 LRRK2,
with 75 to 82% median reduction from baseline averaged over the
12-hour dosing interval on the final dosing day (day 10) at 80 and
100 mg BID. DNL201 treatment reduced urinary BMP concentrations (day 10) in healthy volunteers receiving 80 and 100 mg BID,
consistent with modulation of lysosomal pathways (Fig. 4C).
LRRK2 target and lysosomal pathway engagement were also
evaluated in the phase 1b study in 28 patients with mild to moderate
PD. In patients with PD, a dose-dependent median reduction from
baseline was observed in whole-blood pS935 LRRK2 averaged over
the 12-hour dosing interval on the last dosing day (day 28) [>85%
median reduction from baseline at 50 mg three times daily (TID)
and > 55% median reduction from baseline at 30 mg TID] (Fig. 4D).
In PBMCs from PD patients, pT73 Rab10 was also reduced by a
median from baseline of >79 and ≥87% averaged over the 12-hour

dosing interval on the last dosing day (day 28) in the 30- and 50-mg
TID groups, respectively (Fig. 4E). This effect was associated with a
reduction in urinary BMP concentration with the 50-mg TID dose
(Fig. 4F). This suggested the potential for reversal of the lysosomal
pathway defects that are present in LRRK2G2019S mutation carriers
who show elevated urinary BMP concentrations (19). Overall, the
pharmacodynamic profile and the magnitude of inhibition of LRRK2
with DNL201 were similar among the healthy volunteers and patients with PD. However, the limited sample size of the LRRK2G2019S
carriers did not allow for a meaningful comparison of DNL201 potency among LRRK2G2019S carriers, noncarriers with PD, and healthy
volunteers.

Table 2. Baseline demographics, clinical characteristics, and patient disposition for the phase 1b study.
Patient characteristics

Placebo (n = 7)

DNL201, 30 mg TID (n = 9)

DNL201, 50 mg TID (n = 12)

All patients (n = 28)

Demographics
Age, median (range), years

66 (49–73)

62 (55–73)

57 (37–71)

63 (37–73)

Male sex, n (%)

5 (71)

8 (89)

9 (75)

22 (79)

LRRK2 PD mutation, n (%)

3 (43)

2 (22)

4 (33)

9 (32)

MAOB inhibitor (rasagiline or
selegiline)*

1 (14)

4 (44)

6 (50)

11 (39)

Dopamine replacement

7 (100)

7 (78)

6 (50)

20 (71)

Dopamine agonist

2 (29)

3 (33)

5 (42)

10 (36)

None of the above

0

1 (11)

2 (17)

3 (11)

PD duration, median (range),
years

3.4 (1–6)

3.3 (1–14)

3.6 (0–8)

3.4 (0–14)

Baseline MDS-UPDRS part III
(“off” state) score, median
(range)

29 (16–62)

29 (16–37)

29 (10–63)

29 (10–63)

Baseline MoCA score, median
(range)

29 (26–30)

27 (25–30)

28.5 (26–30)

28 (25–30)

Baseline PD medications, n (%)

Disease status

Disposition, n (%)
Completed treatment

7 (100)

9 (100)

11 (92)

27 (96)

Discontinued study

0

0

1 (8)

1 (4)

Had blinded dose reduction

0

0

1 (8)

1 (4)

*One patient received selegiline, and 10 received rasagiline.
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DNL201 is safe and generally well tolerated in healthy
volunteers and patients with PD
Safety and tolerability of DNL201 were assessed in the phase 1 SAD
and MAD study in healthy volunteers. Sixty-three healthy volunteers
were randomized in the SAD cohorts (age range, 18 to 50 years).
Forty-seven received DNL201 at doses ranging from 10 to 225 mg,
and 16 received placebo for 10 days; this group included 7 elderly
healthy volunteers (mean age, 64.5 years), of whom 5 received
60 mg of the drug and 2 received placebo for 10 days. For the MAD
cohorts, 59 healthy volunteers were randomized, with 48 receiving
DNL201 at doses ranging from 40 mg once daily (QD) to 100 mg
BID and 11 receiving placebo for 10 days; this group included 10
elderly healthy volunteers (8 receiving 80 mg BID DNL201 and 2
receiving placebo) (fig. S7A). The baseline characteristics of the
healthy volunteers are presented in tables S5 and S6.
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A

DNL201 plasma concentration
at day 10 (µM)

Plasma concentration (µM)

10

as measured by steady-state AUC (AUCss) and steady-state Cmax
(Cmax,ss) after BID multiple dosing, was overall slightly greater than
dose proportional over the entire dose range evaluated (25 to 100 mg)
(table S8). Steady state was achieved between days 8 and 10, as evidenced by similar mean AUCss and Cmax,ss values; mean accumulation ratios (AUC0–12h on day 10/AUC0–12h on day 1, and Cmax on
day 10/Cmax on day 1, respectively) were about 1.2- to 2.3-fold for
AUC0–12h and about 1.0- to 1.7-fold for Cmax in the nonelderly
healthy volunteer BID MAD cohorts. After BID dosing at 80 mg for
10 days, the mean ± SD AUCss for DNL201 was greater in elderly
healthy volunteers, 17.5 ± 7.5 M*hour, than in nonelderly healthy
volunteers, 11.8 ± 4.6 M*hour, but with comparable mean ± SD
terminal half-lives of 30.0 ± 9.7 hours versus 27.9 ± 16.3 hours, respectively. CSF–to–unbound plasma concentration ratio mean ± SD
was 1.2 ± 0.15 and 0.87 ± 0.23 in nonelderly healthy volunteers
receiving 25 and 80 mg BID, respectively, using an unbound fraction
of DNL201 in human plasma of 25% (as determined from in vitro
plasma protein binding using ultracentrifugation and equilibrium
dialysis methods). The mean ± SD CSF–to–unbound plasma concentration ratio in elderly healthy volunteers receiving 80 mg BID
was 1.0 ± 0.13 (fig. 5C). These CSF–to–unbound plasma ratios of
DNL201, similar to what was observed in nonclinical species, suggest
a high level of brain exposure for DNL201 in humans.
DNL201 was generally well tolerated in the phase 1 healthy
volunteer study, at doses of ≤150 mg QD in the SAD cohorts
and ≤100 mg BID in the MAD cohorts. No serious adverse events
(SAEs) were observed. The most common treatment-emergent
AEs (TEAEs) in the MAD
cohorts that were more
B
25 mg BID
frequent in those who
40 mg BID
received DNL201 versus
80 mg BID
10.0
80 mg BID (elderly)
placebo were headache
10 mg
100 mg BID
30 mg
(40%), dizziness (13%),
60 mg
60 mg (elderly)
and nausea (13%). Across
100 mg
1.0
150 mg
single and multiple doses,
the nature and frequency
of TEAEs were similar
between the elderly and
0.1
nonelderly healthy volunteer cohorts that received
DNL201.
0.01
In the SAD cohorts,
40
50
0
6
12
3
9
TEAEs
were reported for
Time after dose (hours)
36% (17 of 47 volunteers)
and 19% (3 of 16 volunteers) across all DNL201
dosing and placebo groups,
Fig. 5. Pharmacokinetics of DNL201 in plasma and CSF of healthy
respectively (table S9). All
human volunteers. (A and B) The pharmacokinetics of DNL201 in
TEAEs were mild, with no
plasma of healthy volunteers from the phase 1 SAD cohorts (n = 46)
(A) and phase 1 MAD BID cohorts (n = 40) after 10 days of DNL201
discontinuations from
treatment at different doses (B). (C) DNL201 concentrations in CSF
study drug due to TEAEs.
relative to unbound DNL201 in plasma in the phase 1 study MAD
The most common TEAE
cohorts of nonelderly (n = 29) and elderly (n = 7) healthy volunteers
in DNL201-treated healthy
after 10 days of treatment, with DNL201 doses ranging from 25 to
volunteers across all single-
100 mg BID in the nonelderly cohorts and 80 mg BID in the elderly
dose groups was headache
cohort. Unbound plasma concentrations were calculated from the
(19%, 9 of 47 healthy voluntotal by applying an unbound fraction of 0.25, which was determined
teers). In the MAD coin vitro using pooled human plasma by ultracentrifugation and equihorts, TEAEs were reported
librium dialysis methods. Data are presented as individual patient
in 52% (25 of 48 healthy
data (circles) along with means and SD (error bars).
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In the phase 1b study, DNL201 was investigated in a total of
28 patients with mild to moderate PD receiving standard-of-care
therapy (fig. S7B), with values on the modified Hoehn and Yahr
scale of 1 to 3. The PD patients were treated TID for 28 days with
placebo (n = 7), DNL201 30 mg (n=9), or DNL201 50 mg (n = 12).
Nine patients with PD (32%) had an LRRK2 coding variant: eight
had the PD-associated G2019S mutation, and one had a rare LRRK2
variant of unknown significance (H365N). The baseline characteristics of the patients with PD are presented in Table 2.
In the phase 1 SAD and MAD cohorts of healthy volunteers,
plasma DNL201 concentrations increased with increasing dose
(Fig. 5, A and B, and tables S7 and S8). In the SAD cohorts, DNL201
exposure (AUC and Cmax) increased in a slightly-greater-than-dose-
proportional manner after single-dose oral administration over the
10- to 150-mg dose range. Median time to peak plasma concentration (tmax) for DNL201 was achieved at around 1 to 2 hours after
dose under fasting conditions. In nonelderly healthy volunteers administered a single dose of DNL201 at 10 to 225 mg under fasting
conditions, the mean ± SD terminal elimination half-life ranged
from 7.5 ± 5.2 hours to 14.4 ± 4.4 hours (table S7). In elderly healthy
volunteers receiving the 60-mg single dose, DNL201 exhibited a
slightly longer mean ± SD terminal half-life of 17.4 ± 5.8 hours versus
12.9 ± 3.5 hours and a greater mean ± SD AUC from time zero to
infinity (AUC0–∞) of 7.46 ± 2.62 M*hour versus 4.51 ± 2.43 M*hour
compared to nonelderly healthy volunteers receiving the same dose.
In the MAD cohorts, DNL201 exposure at steady state, the time
after which the concentration of drug in the body remains consistent,
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for both treatment groups. The mean Cmax,ss and AUCss over the
8-hour dosing interval (AUC0–8h,ss) of DNL201 increased in a greater-
than-dose-proportional manner; mean increases in these parameters
were about 1.9- and 2.3-fold, respectively, with an about 1.7-fold
DNL201 dose increase from 30 to 50 mg TID. Clear separation in
drug exposure was observed between the 30- and 50-mg doses
(fig. S8A). The mean ± SD CSF–to–unbound plasma concentrations
were about 1.1 ± 0.12 and 1.3 ± 0.25 for the DNL201 30- and 50-mg
TID groups, respectively (fig. S8B).
In the phase 1b study, DNL201 was generally well tolerated in
patients with PD at doses of 30 or 50 mg TID (Table 3). Most
TEAEs were mild or moderate in severity in both DNL201 groups
in the phase 1b study. A higher incidence of moderate TEAEs was
seen in the 50-mg drug group (50 versus 0% in the placebo and 30-mg
groups). The most common TEAE in the active-treatment groups
was headache (7 of 21 patients, 33%). For both doses of DNL201,
study drug–related TEAEs were generally manageable and reversible.
The 30-mg group had one SAE of Legionella pneumonia, which began
after completion of treatment and was reported as unrelated to
study drug. One event of severe headache in a patient who received
50 mg TID led to a dose reduction; the headache resolved while the
patient received 30 mg TID. One patient receiving 50 mg TID withdrew early from the study after experiencing moderate symptomatic
orthostatic hypotension, moderate headache, and mild nausea.
These events resolved without intervention upon discontinuation
of study drug.
No clinically meaningful changes or dose-related trends in vital
signs were observed with the exception of increased standing heart
rate in two patients receiving 50 mg TID of DNL201. One patient
had preexisting autonomic dysfunction, and one was receiving concomitant -blocker (tamsulosin) treatment; both events were considered possibly related to DNL201. No clinically meaningful changes

Table 3. Common treatment-emergent adverse events in healthy volunteers in the phase 1 MAD cohorts and in the phase 1b PD cohort. For each TEAE,
the number of participants experiencing ≥1 TEAE is shown, and if the participant experienced this TEAE on >1 occasion, it was counted once. TEAEs that
occurred in ≥2 participants in any dosing group are also included.
Phase 1 MAD healthy volunteer cohorts
TEAE, n (%)

PBO
elderly
(n = 2)

PBO
(n = 9)

Phase 1b PD cohort

Total
DNL201
(n = 48)

40 mg
QD
(n = 8)

25 mg
BID
(n = 8)

40 mg
BID
(n = 8)

80 mg
BID
(n = 8)

80 mg
BID
elderly
(n = 8)

25 (52)

3 (38)

0

5 (63)

6 (75)

5 (63)

100 mg
BID
(n = 8)

PBO
(n = 7)

Total
DNL201
(n = 21)

30 mg
TID
(n = 9)

50 mg
TID
(n = 12)

6 (75)

2 (29)

16 (76)

5 (56)

11 (92)
5 (42)

Participants with ≥ 1 TEAE, n (%)
Any TEAE

1 (50)

5 (56)

Volunteers (%) with ≥1 report of most frequent TEAEs across single-dose cohorts (≥2 reports receiving active treatment), n (%)
Headache

1 (50)

0

19 (40)

2 (25)

0

4 (50)

4 (50)

4 (50)

5 (63)

1 (14)

7 (33)

2 (22)

Dizziness

0

0

6 (13)

0

0

2 (25)

0

2 (25)

2 (25)

0

0

0

0

Nausea

0

0

6 (13)

0

0

2 (25)

0

2 (25)

2 (25)

1 (14)

5 (24)

1 (11)

4 (33)

Tremor

0

0

0

0

0

0

0

0

0

1 (14)

4 (19)

0

4 (33)

Fatigue

0

0

0

0

0

0

0

0

0

0

2 (10)

0

2 (17)

Dyskinesia

0

0

0

0

0

0

0

0

0

0

2 (10)

0

2 (17)

Back/
extremity
pain

0

3 (33)

3 (6)

0

0

0

1 (13)

1 (13)

1 (13)

0

0

0

0

Vomiting

0

0

2 (4)

0

0

1 (13)

0

1 (13)

0

0

0

0

0

Palpitations

0

0

2 (4)

0

0

1 (13)

1 (13)

0

0

0

0

0

0
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volunteers) and 55% (6 of 11 healthy volunteers) across all DNL201
dosing and placebo groups, respectively (table 3). Most TEAEs
were mild in severity. TEAEs leading to study drug discontinuation
were reported for three healthy volunteers (two with headache and
one with atrial fibrillation considered unrelated to study drug), all
of whom received DNL201. The most common TEAE in DNL201-
treated healthy volunteers across all MAD cohorts was headache
(40%, 19 of 48). Modest Cmax-related increases in supine heart rate
(about 10 bpm), as well as reductions in supine systolic blood pressure (about 5 to 10 mmHg), occurred at doses ≥100 mg BID and
were generally asymptomatic. The hemodynamic changes were
considered to be possibly related to off-target inhibition of phosphodiesterase (PDE)3A (IC50 of 0.73 M) and PDE5 (IC50 of 1.2 M)
by DNL201. The maximum tolerated dose for DNL201 was 100 mg
BID as healthy volunteers initially given DNL201 at 150 mg BID
required dose reduction to 100 mg BID on day 2 due to reports of
mild dizziness (lightheadedness) in two participants and asymptomatic orthostatic hypotension in another participant.
To mitigate the modest Cmax-related hemodynamic changes observed with BID doses ≥100 mg in the phase 1 study, TID dosing
was implemented in the phase 1b study in patients with PD. After
the first dose of DNL201 on day 1 (30 or 50 mg), the rate of absorption of DNL201 was similar for the two active treatment groups,
with a median (range) for tmax of about 1.6 hours (1.0 to 3.0 hours)
and 1.2 hours (0.97 to 3.0 hours), respectively. Mean Cmax and
AUC0–8h of DNL201 increased in a greater-than-dose-proportional
manner; mean increases in these parameters were about 2.7- and
2.0-fold, respectively, with an about 1.7-fold DNL201 dose increase
from 30 to 50 mg. On day 28, the rate of absorption of DNL201 was
similar for the two treatment groups, with a median (range) tmax of
around 1.0 hour (0.5 to 8.0 hours) and 1.5 hours (1.0 to 4.0 hours),
respectively (table S10). The mean terminal half-life was also similar

SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE
from baseline or dose-related trends in pulmonary function testing
or safety laboratory measures were observed. No dose-dependent
changes were observed in physical or neurological examinations or
the Movement Disorder Society-Unified Parkinson’s Disease Rating
Scale (MDS-UPDRS) Part III, Non-Motor Symptoms Scale, or
Montreal Cognitive Assessment (MoCA) scores; such changes were
not expected on the basis of the 28-day duration of dosing. Furthermore, by using these measures and the Columbia-Suicide Severity
Rating Scale as safety outcomes, no evidence of clinically meaningful
worsening of motor function, mood, or cognition occurred in
patients treated with DNL201.
Treatment with DNL201 was not associated with changes in pulmonary (fig. S9, A to D) or renal function (fig. S10, A and B) across
the phase 1 and 1b studies. No clinically meaningful changes from
baseline or dose-related trends in diffusion capacity for carbon
monoxide or forced vital capacity (fig. S9, A to D) were observed.
Similarly, no clinically meaningful changes in renal function assessed
by serum creatinine, blood urea nitrogen, or urine albumin were
detected (fig. S10, A and B, and tables S11 and S12).

Pathogenic variants in LRRK2 that increase its kinase activity
greatly increase the risk for PD (3, 16, 40, 41). Our data, consistent
with other studies, demonstrate that LRRK2 activity is also increased
in some patients with sporadic PD (9, 10). LRRK2 has been shown
to regulate many aspects of intracellular trafficking, and there is increasing evidence that lysosomal and autophagic defects play a key
role in the pathogenic processes in PD (6, 7). In our studies, DNL201
treatment has been shown to fully normalize lysosomal function in
LRRK2G2019S primary mouse astrocytes and partially restore lysosomal
proteolysis in GBA-variant cells, suggesting that LRRK2 inhibition
may improve lysosomal function.
Here, we evaluated the LRRK2 inhibitor DNL201 in healthy volunteers and patients with PD in a phase 1 and phase 1b clinical trial,
respectively. LRRK2 inhibition by DNL201 in preclinical models, as
measured by phosphorylation of S935 in LRRK2, enabled dose projections for our clinical trials (Figs. 1 and 3). DNL201 modulated
lysosomal endpoints in vitro and in vivo in rodents and nonhuman
primates at clinically relevant doses, achieving about 80% inhibition
of LRRK2 (Figs. 2 and 3). Our phase 1 and phase 1b clinical studies
demonstrated dose-dependent inhibition of LRRK2 through measurement of pS935 LRRK2 and a downstream target of LRRK2, pT73
Rab10, in healthy volunteers and patients with PD, consistent with
preclinical data. Evidence of lysosomal modulation, associated with a
reduction in urinary BMP, was shown in both healthy volunteers and
patients with PD at drug doses that were safe and generally well tolerated.
Together, these results demonstrate that LRRK2 inhibition has potential as a disease-modifying treatment for PD supporting further
investigation in long-term larger clinical trials in patients with PD.
Preclinical translational studies support the use of blood-based
markers for projecting LRRK2 kinase inhibition in the brain of
human volunteers. In nonhuman primates, the pharmacokinetics
of DNL201 were comparable in plasma, CSF, and brain. In addition, pS935 LRRK2 inhibition was also similar in PBMCs and brain
of nonhuman primates, suggesting that peripheral LRRK2 inhibition
predicts inhibition in the CNS. In our phase 1 and phase 1b studies,
DNL201 concentrations were similar in human CSF and plasma
across a broad range of doses. Our data show that LRRK2 inhibition
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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DISCUSSION

was quantitatively related to DNL201 concentrations in preclinical
animal models, healthy volunteers, and patients with PD. Moreover,
the pharmacokinetics are comparable in plasma, CSF, and brain in
nonclinical studies, suggesting that peripheral pharmacodynamics
are likely to indicate the extent of LRRK2 inhibition in the brain
(Fig. 3, C and D). Development of clinically translatable CSF markers
of LRRK2 inhibition and modulation of downstream pathways is
being actively pursued to enable more direct measurement of LRRK2
inhibition in the CNS.
In our phase 1 and phase 1b studies, treatment with DNL201
demonstrated evidence of an impact on lysosomal function based
on a dose-dependent reduction in urinary BMP concentration in
both healthy volunteers and patients with PD. Urinary BMP has
emerged as a potentially important marker of lysosomal function.
Increased LRRK2 kinase activity and an increase in urinary BMP of
about threefold are evident in LRRK2 mutation carriers (19). Treatment with LRRK2 inhibitors reduced LRRK2 kinase activity and
urinary BMP in animals (20). Our clinical trial results are consistent
with this finding, demonstrating a reduction in urine BMP at
DNL201 doses with high LRRK2 inhibition (>80%) in both healthy
volunteers and patients with PD irrespective of LRRK2 mutation,
and suggesting that modulation of lysosomal function is independent of baseline BMP. The >80% inhibition of LRRK2 that was required to observe a reduction in BMP in urine may reflect a change
in extracellular BMP resulting from cellular processes downstream
of LRRK2 due to modulation of lysosomal function rather than
being a direct biochemical target of LRRK2 activity. The relationship
between urine BMP reduction and LRRK2 inhibition will need to be
explored in more detail in future clinical studies.
The underlying mechanism for reduction in urinary BMP that
occurs with LRRK2 inhibition remains unclear; however, changes
in urinary BMP appear to correlate with alterations in lysosomal
function, and BMP has been identified as a potential marker to
measure the impact of LRRK2 inhibition on the lysosomal pathway
(20, 27). LRRK2 inhibition may reduce urinary BMP by modulating
the extracellular transport of BMP-containing vesicles from endo-
lysosomes through mechanisms potentially dependent on Rab phosphorylation, resulting in decreased BMP concentration in urine.
Preclinical data reported here demonstrate that the reduction in
urinary BMP that occurs with LRRK2 inhibition is accompanied by
an increase in renal BMP, suggesting that LRRK2 inhibition may
regulate urine BMP by reducing the extracellular release of BMP-
containing vesicles from kidney tissue.
At drug doses that demonstrate LRRK2 inhibition, on-target
effects in the lung (vacuolation of type II pneumocytes) were
observed in early nonhuman primate studies evaluating LRRK2 inhibitors, delaying the advancement of LRRK2 inhibitors into the
clinic (20). However, with thorough evaluation across multiple
LRRK2 inhibitors at doses expected to demonstrate substantial
kinase inhibition, these on-target changes were found to be nonadverse and reversible, with no measurable functional change (22).
Previous studies described only nonclinical safety of small-molecule
LRRK2 inhibitors in nonhuman primates for ≤28 days of repeat
dosing, in which vacuolation in type II pneumocytes did not affect
lung function tests or surfactant secretion end points (20, 22). In the
current study, long-term treatment with DNL201 in cynomolgus
macaques for 39 weeks, a dosing duration demonstrated to identify
late-occurring toxicities and progression of toxicities (28), showed
sustained drug exposures and nonadverse microscopic findings in
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variant carriers. Reduction in LRRK2 protein of about 50% in lossof-function heterozygous carriers and possibly even up to 100% in
one homozygous adult carrier appeared to demonstrate no impact
on life expectancy and no increase in renal or pulmonary disease or
other conditions (43, 44). Overall, the safety data for DNL201 in nonclinical chronic toxicity studies and the phase 1 and phase 1b clinical
trials provide an acceptable safety profile for continued clinical study.
Our phase 1 and phase 1b studies have several limitations. The
small sample sizes, in particular for the LRRK2 mutation carriers,
limit the comparison of the outcomes in the LRRK2 mutation carriers
compared to patients with sporadic PD. The short duration of this
study was not sufficient to study the clinical efficacy of DNL201,
which would need to be evaluated in larger studies of longer duration. Determining the link between LRRK2-related marker changes
(pS935 LRRK2, pT73 Rab10, and urinary BMP) and clinical improvement in PD also requires longer-term treatment coupled with
efficacy evaluations. Therefore, additional clinical studies are needed
to evaluate whether the reduction in LRRK2 activity and corresponding effects on lysosomal function due to treatment with
LRRK2 inhibitors translate to a reduction in the progression of PD
symptomatology.
Currently, no disease-modifying treatments for PD are available.
Evidence suggests that increased LRRK2 activity is an important
contributor to PD pathology through its effects on the lysosomal
pathway (11). LRRK2 inhibitors represent a new class of investigational therapeutics with the potential to address a key aspect underlying the biology of PD, lysosomal dysfunction, and provide the
possibility of reducing the rate of disease progression. Our nonclinical and human clinical data in healthy volunteers and in patients
with PD have demonstrated the safety and tolerability of DNL201 at
doses with substantial LRRK2 target and lysosomal pathway engagement. DNL201 provides proof of mechanism in humans and demonstrates characteristics of a viable therapeutic. On the basis of the
totality of data to date for two chemically distinct LRRK2 inhibitors,
DNL201 and BIIB122 (DNL151), both have met requirements to
proceed into late-stage clinical studies. Selection of BIIB122 was
made because of its pharmacokinetic properties that provide additional dosing regimen flexibility.
MATERIALS AND METHODS

Study design
This translational study involved evaluation of the underlying biology
of LRRK2-dependent changes in lysosomal morphology in experiments using primary mouse astrocytes and human microglia. To
evaluate DNL201 potency, inhibitory activity, and impact on the
lysosomal pathway, experiments were conducted using cell models
and animals (rodents and cynomolgus macaques). Preclinical toxicology assessments were completed in rodents and cynomolgus
macaques. Clinical studies administering DNL201 in healthy volunteers (phase 1) and patients with PD (phase 1b) were conducted
to evaluate the pharmacokinetics, amount of LRRK2 inhibition,
modulation of lysosomal function, and safety in humans.
Analysis of LRRK2-dependent changes in
lysosomal morphology
H4 cells {human neuroglioma cell line [American Type Culture
Collection (ATCC) catalog no. HTB-148} were plated in 96-well
plates (Cell Carrier Ultra plates, PerkinElmer, Waltham, MA) at a
density of 5000 cells per well in Gibco Dulbecco’s modified Eagle’s
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the lung. Different doses of DNL201 that demonstrated kinase inhibition were associated with increased size and number of lamellar
bodies (lysosome-related organelles) in type II pneumocytes in the
macaque lung. These findings were consistent with previous reports
(20, 22), did not show progression over time compared with shorter
studies, had no discernable functional effects, and were not associated
with secondary degenerative or inflammatory effects (including
evaluations by electron microscopy). These results were considered
nonadverse and were reversible upon cessation of treatment. Therefore, these data indicate that DNL201 has a low risk of affecting respiratory function in humans at doses in the therapeutic range and
support the use of LRRK2 inhibitors for chronic treatment of PD.
In the phase 1 and phase 1b studies reported here, DNL201 was
generally well tolerated across a broad range of doses. These studies
evaluated LRRK2 inhibition in both healthy volunteers and patients
with PD, including DNL201 exposure, degree of LRRK2 inhibition,
safety, and tolerability. There was an increased incidence of headaches in the DNL201-treated versus placebo-treated healthy volunteers and patients with PD. Whereas the potential mechanism for
DNL201-related headaches is unclear, PDE5 inhibition is a consideration given that headaches have been known to occur in individuals taking PDE5 inhibitors (42). Lumbar punctures were used in
both studies, which may have also contributed to the headaches.
PD patients with and without LRRK2 mutations were included
in the phase 1b study to obtain a preliminary assessment of potential
pharmacokinetic, pharmacodynamic (pS935 LRRK2, pT73 Rab10,
or BMP), and safety differences in LRRK2 mutation carriers. The
number of enrolled patients with LRRK2 mutations was small, comprising about one-third of the phase 1b population. However, on
the basis of this study, no genotype-associated differences were
apparent in the outcomes. In addition, it was important to evaluate
whether patients with PD were more susceptible to drug-induced
AEs compared with healthy volunteers. Potential off-target, hemodynamic effects of PDE3 or PDE5 inhibition were prospectively
monitored as blood pressure effects may differ in patients with PD
because of disease-related autonomic dysfunction or concomitant use
of dopaminergic medications. PDE5 inhibitor medications were excluded during the study; however, other vasodilators were allowed.
Coadministration of an -blocker with DNL201 was associated with
orthostatic hypotension in one patient. There did not appear to be
increased sensitivity of patients with PD to blood pressure changes
during treatment with DNL201 compared to healthy volunteers;
however, the potential for hemodynamic effects of DNL201 and
specific drug-drug interactions warrants further study. The potential PDE3 and PDE5 inhibitory effects appeared to be off-target effects specific to DNL201 rather than LRRK2 inhibitors in general.
Overall, the pharmacokinetic profile, extent of LRRK2 inhibition, and
safety in patients with PD were similar to those in healthy volunteers.
In our human studies, no clinically meaningful changes in pulmonary or renal function were observed during a 28-day treatment
period at drug doses demonstrating substantial LRRK2 inhibition
and lysosomal pathway engagement. However, the possibility of
unforeseen adverse events with sustained high LRRK2 inhibition in
humans over months to years cannot be excluded. Therefore, future
studies of LRRK2 inhibitors should evaluate safety over a longer
treatment period at doses demonstrating near-maximal inhibition
with evidence for modulation of lysosomal biomarkers. Support for
the safety of long-term LRRK2 inhibition may be derived from two
independent studies evaluating LRRK2 loss-of-function genetic
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Lysosomal protein turnover analysis in primary mouse
astrocytes and Gaucher patient fibroblasts
To determine whether LRRK2 G2019S expression altered protein
turnover and whether kinase activity improved lysosomal function,
protein turnover via lysosomes was quantified using a modified,
previously described, high-throughput, imaging-based assay (43).
Primary mixed glial cultures from postnatal (P1 to P3) wild-type
and LRRK2G2019S KI mice (C57BL/6-Lrrk2tm4.1Arte; originally
generated by the Michael J. Fox Foundation, New York, NY) maintained on a C57BL/6NTac genetic background were used for these
studies (Taconic, model no 13940) (44). This model is a constitutive
knockin of the human G2019S point mutation into exon 41 of the
mouse LRRK2 gene. To determine whether GBA variant cells had
altered lysosomal protein turnover and whether LRRK2 kinase inhibition may modulate lysosomal proteolysis in these cells, Gaucher
disease type 2 fibroblasts that were homozygous for the L444P variant
and age-matched healthy control fibroblasts were obtained from
Coriell Institute for Medical Research Biobank (catalog IDs: GM03349,
GM05565, GM05659, GM08760, and GM00877).
Protein turnover was measured using l-azidohomoalanine (AHA)
labeling to quantify long-lived protein degradation. AHA is used as
a surrogate for l-methionine, and the AHA probe is incorporated
into proteins during protein synthesis. After a short chase to remove
short-lived proteins, the amount of long-lived AHA-containing
proteins was visualized through a “click” reaction between the AHA
probe and a fluorescently tagged alkyne probe. Briefly, mixed glial
cells were plated into a 96-well plate at a density of 50,000 cells per
well. Cells were treated with either vehicle or 2 M (micromolar)
DNL201 24 hours before AHA labeling and were maintained in
the medium for the duration of the study. After 24 hours, the
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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medium was replaced with methionine-free medium with or without AHA (negative control for staining). After 16 to 18 hours of
labeling, the medium without AHA and containing a 10× excess of
methionine was added for 2 hours. Cells were then incubated in
DMEM +10% FBS with 10× methionine alone or supplemented
with 50 nmol bafilomycin A (to assess the lysosomal component of
long-lived degradation) for 24 hours. Cells were fixed with 4% PFA
and permeabilized with 0.05% Triton X-100, and then the click
reaction occurred between the azide group of AHA and an Alexa
488–conjugated alkyne probe (TFS) to label all AHA-containing
proteins within cells. Cells were then labeled with DAPI and HCS
CellMask Deep Red to visualize the nuclei and cytoplasm of each
cell. Cells were imaged using the Opera Phenix spinning-disk confocal microscope (40× water objective; 405, 488, and 647 laser lines).
Imaging analysis was performed using Harmony software
(PerkinElmer). Briefly, nuclei were identified using the DAPI stain
to identify individual cells, and the cytoplasmic area for each cell was
identified using the HCS CellMask Deep Red signal. AHA-containing
proteins per cell were quantified by measuring the average intensity
of the 488-modified AHA probe per cell.
Measurement of DNL201 potency in human PBMCs
LRRK2G2019S carriers and noncarriers (with and without a self-
reported PD diagnosis) were recruited from 2016 to 2017 {study IDs:
SAN-BB-01 [approved by Quorum Review independent review
board (IRB)], PLMDEN201609v1 (approved by New England IRB),
and US-IRB-13-2016.1 (approved by E&I Review Services)}. PBMCs
from two donors for pS935 LRRK2 and pT73 Rab10 dose-response
comparison were obtained from AllCells (Alameda, CA).
Cryopreserved PBMC vials were rapidly thawed in a water bath.
Cells were briefly washed twice and plated in PBMC medium
[RPMI 1640 with GlutaMAX (TFS, Waltham, MA), 10% heat-
inactivated FBS, and 1% penicillin-streptomycin] in a 96-well round-
bottom plate at 3,000,000 cells per well (for pT73 Rab10/pS935
LRRK2 comparison) or 300,000 cells per well (for comparison of
potency in LRRK2G2019S carrier PBMCs). Dilutions of DNL201 were
prepared by serial dilution of a 50 mM working stock of DNL201 in
DMSO into PBMC medium. The PBMC/DNL201 mixture was
incubated for 1 hour at 37°C. Cells were briefly resuspended, transferred to a 96-well round-bottom plate, briefly centrifuged, and
then resuspended in ice-cold PBMC lysis buffer [1× cell lysis buffer
(Cell Signaling Technology, Danvers, MA, catalog no. 9803) with
PhosSTOP phosphatase inhibitor (Sigma-Aldrich, St. Louis, MO,
04906837001), complete protease inhibitor (Roche, Basel, Switzerland,
04693159001), and Benzonase (Sigma-Aldrich; E8263)]. Lysates
were placed on ice for 20 min and then spun at maximum speed in
a benchtop centrifuge for 20 min at 4°C. Supernatants were collected
into new plates for pS935 LRRK2 and pT73 Rab10 immunoassay
analysis in 96-well format as described below. DNL201 concentrations were adjusted for protein binding in 10% FBS (70% unbound).
Data were fit to a four-parameter logistic curve in GraphPad Prism
version 8 (GraphPad, San Diego, CA).
Measurement of DNL201’s inhibition of LRRK2 in HEK293T cells
HEK293T cells (ATCC, CRL-11268) were seeded and incubated (see
the Supplementary Materials and Methods for full description). Using
the incubated HEK293T cells, 100 l of the compound-containing
medium was replaced with 100 l of lysis buffer. The plates were
sealed, shaken at 4°C for 30 min, and then stored at −20°C. On day 5,
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medium [DMEM, Thermo Fisher Scientific (TFS), Waltham, MA]
and 10% fetal bovine serum (FBS). After 24 hours, lentiviruses
encoding green fluorescent protein (GFP)–LRRK2 or GFP-LRRK2
G2019S (purchased from KU Leuven viral core, KU Leuven, Leuven,
Belgium) were added to the H4 cells (final volume, 100 l of medium
per well, targeting multiplicity of infection of 3). About 18 hours
later, medium was removed and exchanged for DMEM/10% FBS
plus dimethyl sulfoxide (DMSO) (vehicle) or 0.3 M DNL201. Two
days later, fresh medium (with vehicle or DNL201) was added, and
cells were incubated for an additional 24 hours (72 hours total treatment with vehicle or DNL201). Cells were fixed in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) and permeabilized
with 0.01% Triton X-100 in 10% normal goat serum in PBS (blocking
buffer). Cells were labeled using mouse anti-Lamp2 (H4B4, Abcam,
Cambridge, UK) overnight at 4°C and followed by secondary detection using Alexa 568–conjugated goat anti-mouse, 4′,6-diamidino-
2-phenylindole (DAPI), and HCS Cell Mask Deep Red (TFS). Cells
were imaged using the Opera Phenix spinning-disk confocal microscope (PerkinElmer) (63× water objective; 405, 561, and 640 laser lines).
Imaging analysis was performed using Harmony software
(PerkinElmer). Nuclei were identified using DAPI stain to identify
individual cells, and the cytoplasmic area for each cell was identified using the HCS CellMask Deep Red signal. The spot analysis building block
was used to identify individual lysosomes (using anti-LAMP2 signal).
The percentage of cells with coalesced lysosomes, defined as ≥1 lysosome >3 m in diameter, were divided by the total number of cells analyzed. These values were shown as a percentage of cells within separate
experiments that contained any lysosomes with a diameter >3 m.
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Immunoassays
pS935 LRRK2 and pT73 Rab10 analyses were performed as previously described (36). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) analysis was performed according to the manufacturer’s
instructions (MSD catalog no. K151PWD).
Measurement of DNL201 potency in iMG
Human iMG were generated as previously described (45). Dose-
response curves for both pS935 LRRK2 and pT73 Rab10 were
generated in wild-type human iMG after treatment with varying
concentrations of DNL201. Working dilutions of DNL201 were
prepared by serial dilution of a 50 mM working stock of DNL201 in
DMSO in C+++ medium, and wild-type iMG were incubated in the
presence of DNL201 for 1 hour at 37°C. Cells were briefly washed in
ice-cold PBS and then resuspended in ice-cold PBMC lysis buffer
[1× cell lysis buffer (Cell Signaling Technology, Danvers, MA, catalog no. 9803) with PhosSTOP phosphatase inhibitor (Sigma-
Aldrich, St. Louis, MO, 04906837001), complete protease inhibitor
(Roche, Basel, Switzerland, 04693159001), and Benzonase (Sigma-
Aldrich, E8263)]. Lysates were placed on ice for 20 min, transferred
to a 96-well V-bottom plate (Falcon, no. 353263), and then spun at
maximum speed in a benchtop centrifuge for 20 min at 4°C. Supernatants were collected into new plates for pS935 LRRK2 and pT73
Rab10 MSD-based analysis in a 96-well format as described above.
DNL201 concentrations were adjusted for protein binding in 10%
FBS. Data were fit to a four-parameter logistic curve in GraphPad
Prism version 8 (GraphPad, San Diego, CA).
Nonclinical repeated dose toxicological assessments
The in-life phase (including clinical, ophthalmic, physical, respiratory, electrocardiogram, and neurological examinations), clinical
pathology evaluation, necropsy, biospecimen collection, anatomic
Jennings et al., Sci. Transl. Med. 14, eabj2658 (2022)
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pathology evaluation, toxicokinetic assessment, and electron microscopy evaluation of the lungs were conducted at Covance Laboratories
(Princeton, NJ). Histopathologic evaluation included a comprehensive tissue list and enhanced sampling and histopathology of the
CNS. All scheduled necropsies were conducted about 24 hours after
the last dose, and the expected Cmax of the compounds was tested.
Studies were conducted in 44 cynomolgus macaques (Macaca
fascicularis) of Chinese origin, aged 26 to 36 months and weighing
1.9 to 2.7 kg at the start of the study (Covance, Princeton, NJ). The
following doses were evaluated: 8, 16, and 32 mg/kg per day, as well
as a vehicle control. Dose formulations were administered twice
daily (BID) by oral gavage for 39 weeks at a dose volume of 5 ml/kg
per dose (10 ml/kg per day). The second daily dose was administered
6 hours (+30 min) after the first daily dose.
Analysis of BMP concentrations in kidney and urine of
wild-type and LRRK2G2019S KI mice after LRRK2 inhibition
LRRK2G2019S KI mice (C57BL/6-Lrrk2tm4.1Arte) were maintained
on a C57BL/6NTac genetic background at Taconic Biosciences Inc.
(Germantown, NY). Adult (7 to 9 months old) LRRK2G2019S KI
mice and their wild-type littermates were age-matched across treatment groups for experiments. MLi-2 (MedChemExpress, Monmouth
Junction, NJ) was used as a tool LRRK2 inhibitor for in vivo experiments. Rodent chow with 10 kcal% fat and cornstarch was formulated into pellets containing MLi-2 (1000 ppm; 100 mg/kg diet)
and irradiated for in-diet dosing (Research Diets Inc., New Brunswick,
NJ; control diet D01060501i, MLi-2 diet D20040204i). Mice were
provided vehicle or MLi-2 diet ad libitum for 7 days. Food weight
and mouse body weight were monitored daily to evaluate diet consumption and animal health.
Urine was collected at baseline 1 day before the initiation of
in-diet dosing and at terminal collection after 7 days of in-diet dosing.
Urine samples were snap-frozen on dry ice and transferred to −80°C
for storage. After 7 days of in-diet dosing, mice were euthanized for
terminal collection of kidney samples. Mice were anesthetized with
2.5% tribromoethanol. Once deeply anesthetized, animals were transcardially perfused with ice-cold PBS using a peristaltic pump for a
minimum of 3 min at a rate of 5 ml/min. After perfusion, the left
kidney was removed and subdissected into the renal cortex and
medulla. Each portion was weighed (20 ± 2 mg), collected in 1.5-ml
Eppendorf tubes, frozen on dry ice, and stored at −80°C. Urine samples were prepared for BMP extraction, and extracted BMP species
were quantified (see the Supplementary Materials for details).
Phase 1 study design
The phase 1, randomized, double-blind, placebo-controlled SAD
and MAD oral dose study was conducted in healthy volunteers and
elderly healthy volunteers (fig. S7, A and B). Primary objectives
were to investigate the safety, tolerability, and plasma pharmacokinetics of single and multiple oral doses of DNL201. Secondary
objectives included characterization of CSF DNL201 concentrations
and whole-blood pS935 LRRK2 (pharmacodynamic marker). Exploratory marker measures were PBMC pT73 Rab10 and urine
BMP (22:6/22:6).
The study was conducted at a single clinical research unit (CRU)
in the United States and included SAD dosing cohorts (DNL201, 10
to 225 mg), MAD dosing cohorts (40 mg QD, 40 to 100 mg BID),
and a MAD elderly healthy volunteer cohort (80 mg BID) (fig. S7, A
and C). Eligible participants were randomized to receive DNL201
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the Flag antibody (monoclonal ANTI-FLAG, M2 antibody, Sigma-
Aldrich, F3165) was diluted (2 g/25 l per well) in PBS [50 l
(3.9 g/l) of FLAG antibody +2.5 ml PBS], added into an MSD
plate (MSD-L15XB-3), and incubated for 2 hours at room temperature. The plate was centrifuged at 1000 rpm for 10 s and shaken with
multidrop for 10 s. The Flag antibody was then discarded and washed
two times with 300 l per well. Then, 50 l per well of block buffer
(LiCor, 927-40000) was added, and the plates were incubated for
2 hours at room temperature. The Flag antibody was again discarded
and washed two times with 300 l per well. The cell lysate (25 l)
was then transferred into a 96-well MSD plate and incubated for
1 hour at room temperature. The lysate was discarded and washed
three times with 300 l per well of wash buffer. The pS1292 antibody (Abcam, 203181) was diluted (1:100) with blocking buffer by
adding 25 l per well of antibody into a 96-well plate. In the case of
pS935 antibody (Abcam, 133450), it was diluted (1:200). The antibody was then discarded and washed three times with 300 l per well
(96-well plate). The sulfotag goat anti-rabbit antibody (R32AB-1)
was diluted (1:500) with blocking buffer by adding 25 l per well of
antibody into a 96-well plate and then incubated for 1 hour at room
temperature. The antibody was then discarded and washed three times
with 300 l per well. A 2× reading buffer was prepared by a 1:1 dilution of 4× MSD reading buffer (MSD-R92TC-1) with MilliQ water.
The wash buffer was then discarded by adding 150 l per well of
2× reading buffer into each well. After a 3-min incubation, the MSD
plates were read within 15 min.
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or placebo in a 3:1 ratio in SAD cohorts and in a 4:1 ratio in MAD
cohorts. Eligible participants were male and female healthy volunteers
aged 18 to 50 years (nonelderly cohorts) or 60 to 75 years (elderly
cohorts), inclusive, with a body mass index between 18.5 and
31.0 kg/m2 (nonelderly cohorts), or 18.5 and 35.0 kg/m2 (elderly
cohorts), inclusive, and a weight of ≥50.0 kg.

Study outcomes
In both studies, safety and tolerability were assessed by AE monitoring, clinical laboratory tests (blood chemistries, hematology, and
urinalysis), vital signs, electrocardiograms, physical and neurological
examinations, and neurological assessments. For the multiple-dose
cohorts only, the Columbia Suicide Severity Rating Scale and pulmonary function tests were assessed. Plasma and CSF pharmacokinetic parameters were evaluated. Pharmacodynamic assessments
included percent change from baseline in whole-blood pS935 LRRK2,
PBMC pT73 Rab10, and urine BMP (22:6/22:6). Average reduction
from baseline in whole-blood pS935 LRRK2 and PBMC pT73 Rab10
over the dosing interval at steady state was calculated. Urine BMP
(22:6/22:6) concentrations were reported as a ratio to urine creatinine
concentrations [BMP (ng)/creatinine (mg)].
Statistics
Preclinical studies
Statistical comparison of the LRRK2 G2019S groups with and without
DNL201 treatment in Fig. 2A was performed by an unpaired t test.
Data in Fig. 2 (B and C) were normalized to the median value within
each experiment and then to the wild-type (B) and control (C)
vehicle-treated groups, respectively. Statistical significance was determined using two-way analysis of variance (ANOVA) with multiple comparison adjustments based on Dunnett’s method. Relative
abundance BMP values in fig. 3 (E to G) were log-transformed and
analyzed using an analysis of covariance (ANCOVA) model with
terms for treatment, genotype, and treatment by genotype interaction, with adjustment by sex, and for urine, by predose BMP
concentrations. Statistical significance was assessed at nominal
significance levels. For fig. S1 (A and B), IC50 values for the pS935
LRRK2 dose-response curves between groups were compared using
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Phase 1b study design
The multicenter, randomized, double-blind, and placebo-controlled
phase 1b clinical trial (NCT03710707) evaluated placebo, DNL201
30 mg, and DNL201 50 mg TID in patients with PD (fig. S7, C and D).
The primary objective was to evaluate the safety and tolerability of
DNL201 administered TID for 28 days. Secondary objectives were
to characterize plasma DNL201 PK and CSF concentrations, wholeblood pS935 LRRK2, and PBMC pT73 Rab10. Exploratory marker
measures were urine BMP (22:6/22:6) and CSF LRRK2.
The study was conducted at eight CRUs in the United States in
two parts: Part 1 was a sentinel cohort (n = 4) randomized to placebo
or DNL201 30 mg TID (1:3 ratio); part 2 included the remainder of
patients (n = 24) randomized to placebo, DNL201 30 mg TID, or
DNL201 50 mg TID (1:1:2 ratio) (fig. S7, B and D).
Eligible participants were men or women aged 30 to 80 years
with a diagnosis of mild to moderate PD, Hoehn and Yahr scale 1 to
3, and the presence or absence of an LRRK2 mutation. Patients with
a MoCA score <24; clinically meaningful hepatic, pulmonary, or
renal disorders; atypical forms of Parkinsonism; or neurological
disorders other than PD were excluded.

a global F test of the best-fit four-parameter logistic curves, in
GraphPad Prism version 8. In fig. S5, pairwise group comparisons
were performed using a linear mixed-effects model on log-transformed
values, accounting for repeat patient measurements among a subset
of the samples, with adjustment by age and sex. Nominal P values
were presented. All statistical tests were performed two-sided.
Clinical studies
Sample sizes were not based on power calculations but were considered sufficient to achieve the study objectives. For each study, data
were summarized by treatment group (pooled placebo group and
each DNL201 dose group). Demographic and other baseline characteristics, safety, pharmacokinetics, and pharmacodynamic data
were summarized using descriptive statistics. The incidence of
TEAEs was summarized for the safety population (treated participants). TEAEs were defined as AEs that occurred or worsened after
initiation of study drug.
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A big step forward for Parkinson’s disease
Inhibition of LRRK2 has emerged as a promising disease-modifying therapeutic target for Parkinson’s disease.
Jennings et al. now report evidence that DNL201, a first-in-class CNS-penetrant LRRK2 kinase inhibitor, reduces
LRRK2 activity and restores lysosomal function in cellular and animal models. In healthy volunteers and patients with
Parkinson’s disease, DNL201 inhibited LRRK2 kinase activity and demonstrated an impact on lysosomal function at
doses that were safe and generally well tolerated. As discussed in a related Focus, these findings provide support for
advancing the investigation of LRRK2 inhibitors to late-stage clinical studies in patients with Parkinson’s disease.

